title: Use of rivaroxaban could trim hospital spending in treating pulmonary embolism.
authors.forename: Mary K
authors.initials: MK
authors.lastname: Caffrey
mesh_terms: D000284:Administration, Oral; D002309:Cardiology / Q000379:methods / Q000592:standards; D003226:Congresses as Topic; D004359:Drug Therapy, Combination; D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006760:Hospitalization / Q000191:economics / Q000331:legislation & jurisprudence; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay / Q000191:economics* / Q000331:legislation & jurisprudence; D009025:Morpholines / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000188:drug therapy*; D000069552:Rivaroxaban; D012955:Societies, Medical; D013876:Thiophenes / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*
chemical_list: D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D009025:Morpholines; D013876:Thiophenes; D006493:Heparin; D000069552:Rivaroxaban